(NASDAQ: TTRX) Turn Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 104.9%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 3,355.66%.
Turn Therapeutics's earnings in 2026 is N/A.On average, 4 Wall Street analysts forecast TTRX's earnings for 2026 to be -$3,303,750, with the lowest TTRX earnings forecast at -$3,462,754, and the highest TTRX earnings forecast at -$3,091,744.
In 2027, TTRX is forecast to generate -$7,658,692 in earnings, with the lowest earnings forecast at -$10,388,261 and the highest earnings forecast at -$4,637,616.